A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.

If you have metastatic non-small-cell lung cancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March 2025 issue of Lung Cancer by Shahnam et al. KRAS G12D and G12C mutations exh ...

Gavreto selectively inhibits the RET fusion protein, driving tumor growth in 1-2% of NSCLC cases, primarily in adenocarcinoma histology. Gavreto is recommended as a first-line treatment for metastatic ...

For the patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations, first-line treatment with sugemalimab has been approved by both the European ...

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...